139 related articles for article (PubMed ID: 30016091)
1. Unraveling the Prenylation-Cancer Paradox in Multiple Myeloma with Novel Geranylgeranyl Pyrophosphate Synthase (GGPPS) Inhibitors.
Lacbay CM; Waller DD; Park J; Gómez Palou M; Vincent F; Huang XF; Ta V; Berghuis AM; Sebag M; Tsantrizos YS
J Med Chem; 2018 Aug; 61(15):6904-6917. PubMed ID: 30016091
[TBL] [Abstract][Full Text] [Related]
2. Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase.
Wiemer AJ; Tong H; Swanson KM; Hohl RJ
Biochem Biophys Res Commun; 2007 Feb; 353(4):921-5. PubMed ID: 17208200
[TBL] [Abstract][Full Text] [Related]
3. Discovery and Evaluation of C6-Substituted Pyrazolopyrimidine-Based Bisphosphonate Inhibitors of the Human Geranylgeranyl Pyrophosphate Synthase and Evaluation of Their Antitumor Efficacy in Multiple Myeloma, Pancreatic Ductal Adenocarcinoma, and Colorectal Cancer.
Boutin R; Lee HF; Guan TL; Nguyen TT; Huang XF; Waller DD; Lu J; Christine Chio II; Michel RP; Sebag M; Tsantrizos YS
J Med Chem; 2023 Dec; 66(23):15776-15800. PubMed ID: 37982711
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and Evaluation of Structurally Diverse C-2-Substituted Thienopyrimidine-Based Inhibitors of the Human Geranylgeranyl Pyrophosphate Synthase.
Lee HF; Lacbay CM; Boutin R; Matralis AN; Park J; Waller DD; Guan TL; Sebag M; Tsantrizos YS
J Med Chem; 2022 Feb; 65(3):2471-2496. PubMed ID: 35077178
[TBL] [Abstract][Full Text] [Related]
5. Thienopyrimidine bisphosphonate (ThPBP) inhibitors of the human farnesyl pyrophosphate synthase: optimization and characterization of the mode of inhibition.
Leung CY; Park J; De Schutter JW; Sebag M; Berghuis AM; Tsantrizos YS
J Med Chem; 2013 Oct; 56(20):7939-50. PubMed ID: 23998921
[TBL] [Abstract][Full Text] [Related]
6. Moiety-linkage map reveals selective nonbisphosphonate inhibitors of human geranylgeranyl diphosphate synthase.
Chen SH; Lin SW; Lin SR; Liang PH; Yang JM
J Chem Inf Model; 2013 Sep; 53(9):2299-311. PubMed ID: 23919676
[TBL] [Abstract][Full Text] [Related]
7. Novel bisphosphonate inhibitors of the human farnesyl pyrophosphate synthase.
De Schutter JW; Zaretsky S; Welbourn S; Pause A; Tsantrizos YS
Bioorg Med Chem Lett; 2010 Oct; 20(19):5781-6. PubMed ID: 20801032
[TBL] [Abstract][Full Text] [Related]
8. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
Morgan MA; Sebil T; Aydilek E; Peest D; Ganser A; Reuter CW
Br J Haematol; 2005 Sep; 130(6):912-25. PubMed ID: 16156861
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells.
Roelofs AJ; Hulley PA; Meijer A; Ebetino FH; Russell RG; Shipman CM
Int J Cancer; 2006 Sep; 119(6):1254-61. PubMed ID: 16619218
[TBL] [Abstract][Full Text] [Related]
10. ω-Hydroxy isoprenoid bisphosphonates as linkable GGDPS inhibitors.
Bhuiyan NH; Varney ML; Bhattacharya DS; Payne WM; Mohs AM; Holstein SA; Wiemer DF
Bioorg Med Chem Lett; 2019 Oct; 29(19):126633. PubMed ID: 31474482
[TBL] [Abstract][Full Text] [Related]
11. The crystal structure of human geranylgeranyl pyrophosphate synthase reveals a novel hexameric arrangement and inhibitory product binding.
Kavanagh KL; Dunford JE; Bunkoczi G; Russell RGG; Oppermann U
J Biol Chem; 2006 Aug; 281(31):22004-22012. PubMed ID: 16698791
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels.
van de Donk NW; Kamphuis MM; van Kessel B; Lokhorst HM; Bloem AC
Blood; 2003 Nov; 102(9):3354-62. PubMed ID: 12855556
[TBL] [Abstract][Full Text] [Related]
13. Metal Coordination Is Crucial for Geranylgeranyl Diphosphate Synthase-Bisphosphonate Interactions: A Crystallographic and Computational Analysis.
Lisnyansky M; Yariv E; Segal O; Marom M; Loewenstein A; Ben-Tal N; Giladi M; Haitin Y
Mol Pharmacol; 2019 Nov; 96(5):580-588. PubMed ID: 31427399
[TBL] [Abstract][Full Text] [Related]
14. The effects of direct inhibition of geranylgeranyl pyrophosphate synthase on osteoblast differentiation.
Weivoda MM; Hohl RJ
J Cell Biochem; 2011 Jun; 112(6):1506-13. PubMed ID: 21503955
[TBL] [Abstract][Full Text] [Related]
15. Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis.
Savino S; Toscano A; Purgatorio R; Profilo E; Laghezza A; Tortorella P; Angelelli M; Cellamare S; Scala R; Tricarico D; Marobbio CMT; Perna F; Vitale P; Agamennone M; Dimiccoli V; Tolomeo A; Scilimati A
Eur J Med Chem; 2018 Oct; 158():184-200. PubMed ID: 30216851
[TBL] [Abstract][Full Text] [Related]
16. Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis.
Reilly JE; Neighbors JD; Tong H; Henry MD; Hohl RJ
Clin Exp Metastasis; 2015 Aug; 32(6):555-66. PubMed ID: 26070429
[TBL] [Abstract][Full Text] [Related]
17. Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitors.
Berndt N; Sebti SM
Nat Protoc; 2011 Oct; 6(11):1775-91. PubMed ID: 22036881
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in the Development of Mammalian Geranylgeranyl Diphosphate Synthase Inhibitors.
Haney SL; Wills VS; Wiemer DF; Holstein SA
Molecules; 2017 May; 22(6):. PubMed ID: 28555000
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms for autophagy modulation by isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells.
Dykstra KM; Allen C; Born EJ; Tong H; Holstein SA
Oncotarget; 2015 Dec; 6(39):41535-49. PubMed ID: 26595805
[TBL] [Abstract][Full Text] [Related]
20. Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo.
Coxon FP; Ebetino FH; Mules EH; Seabra MC; McKenna CE; Rogers MJ
Bone; 2005 Sep; 37(3):349-58. PubMed ID: 16006204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
